Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104703 | 0.78 | MAPT (0.38) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL11339077 | 0.76 | MAPT (0.37) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL4786220 | 0.76 | MAPT (0.37) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL29245722 | 0.76 | MAPT (0.41) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL1976593 | 0.74 | MAPT (0.36) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL16363146 | 0.73 | MAPT (0.42) | SMN1; SMN2MAPTRECQLMEN1TSHR | |
| SCHEMBL11328965 | 0.72 | — | — | |
| SCHEMBL13190837 | 0.66 | — | — | |
| SCHEMBL13190522 | 0.66 | — | — | |
| SCHEMBL13093073 | 0.66 | MAPT (0.38) | SMN1; SMN2MAPTRECQLMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ADRB3, SLC6A3, NR3C2 | SMN1; SMN2 1423/4885MAPT 4640/4885RECQL 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.